Philippe Ronga
Darmstadt, HE 64293, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Real-world healthcare resource utilization and costs of weekly versus every-2-week cetuximab in metastatic colorectal cancer.
Journal: Journal of comparative effectiveness research
Published: January 27, 2021
Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population.
Journal: Journal of comparative effectiveness research
Published: October 29, 2020
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study.
Journal: Journal of medical economics
Published: January 07, 2020
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors.
Journal: Frontiers in oncology
Published: April 25, 2019
A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: July 20, 2017
Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.
Journal: Molecular oncology
Published: August 12, 2016
FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: February 01, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026